Overview
Much has changed in the treatment landscape of non-small cell lung cancer (NSCLC) over the last few years. Newer generations of oral drugs for patient with EGFR mutations or ALK translocations show better efficacy and safety. Immunotherapy is being integrated in every aspect of the management of this disease. Combination chemotherapy and immunotherapy has received FDA approval for frontline treatment. The challenge now is to decide what is the best treatment option for our patients and how to navigate this rapidly evolving field.
After viewing this program attendees will be able to:
- Recognize the status and use of novel systemic treatments for advanced stage NSCLC therapy;
- Identify individual patient selection criteria for specific therapies;
- Define ongoing and planned clinical trials that are most likely will impact patient treatment in the near future.
Hossein Borghaei, MS, DO
Associate Professor, Chief, Thoracic Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA.
Ramaswamy Govindan, MD - Program Chair
Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.
For any inquiries, please contact meetings@iaslc.org.
After viewing this program attendees will be able to:
- Recognize the status and use of novel systemic treatments for advanced stage NSCLC therapy;
- Identify individual patient selection criteria for specific therapies;
- Define ongoing and planned clinical trials that are most likely will impact patient treatment in the near future.
Hossein Borghaei, MS, DO
Associate Professor, Chief, Thoracic Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA.
Ramaswamy Govindan, MD - Program Chair
Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.
For any inquiries, please contact meetings@iaslc.org.